PT-141

PT-141 (Bremelanotide) Nasal Spray is supplied by Crystal Peptides as a catalogued research material in the following format and strength: nasal spray, 10mg/10ml. This presentation identifies the catalogue product; its batch-specific composition and analytical characteristics must be established from the corresponding documentation.

PT-141 denotes bremelanotide, a conformationally constrained cyclic peptide and melanocortin-receptor ligand. It is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) and an active metabolite of Melanotan II, distinguished by a C-terminal carboxyl group rather than an amide. Registry values commonly describe the free active moiety; an acetate form or other batch-specific counter-ion composition requires confirmation.

Chemical properties and registry information

Registry identifiers and molecular values refer to the defined peptide entity, not the complete spray formulation. They do not independently establish the composition or identity of a supplied batch.

Research background and published evidence

Published research

Published work on bremelanotide addresses melanocortin-receptor pharmacology, including receptor binding, receptor-subtype selectivity and downstream cell signalling. Its cyclic scaffold also provides a context for structure–activity comparisons with related melanocortin ligands. Interpretation requires attention to the molecular form, experimental system and analytical methods described in each publication.

Current scientific understanding

Compound-level pharmacology is distinct from evidence about a finished formulation. Receptor-assay findings do not authenticate this catalogue product or establish equivalence to a published research material. Although bremelanotide is an established medicinal active substance in some jurisdictions, documentation for an authorised medicinal product does not characterise this research-only nasal spray or its individual lots.

Formulation note

The published research background predominantly concerns other materials, formulations or routes rather than this specific catalogue presentation. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. Differences in excipients, counter-ion composition and formulation matrix require separate consideration when evaluating analytical comparability. The stated catalogue strength alone does not establish equivalence to any material described in the literature.

Quality and testing

Quality information must be linked to a batch-specific certificate of analysis (CoA) matching this product, presentation and lot. The CoA and safety data sheet (SDS) should be checked for the stated material identity, formulation details and documented test scope. Reports for another lot, presentation or similarly named compound are not evidence for this product.

Identity, chromatographic area purity, analyte content, counter-ion content, microbiological attributes and elemental impurities are separate measurements. A result for one does not establish the others. Only tests supported by a matching report should be regarded as documented; unreported attributes must not be inferred from the product name, registry entry or spray format.

Supplied exclusively for laboratory research by qualified professionals. Not for human or veterinary use. No dosing directions are provided. Purchasers are responsible for compliance with applicable institutional and local requirements.